

33. **Leininger JR**, Jokinen MP. Tumours of the oral cavity, pharynx, oesophagus and stomach. *IARC Sci Publ* 1994;167–93.
34. **Rogers AB**, Taylor NS, Whary MT, *et al.* *Helicobacter pylori* but not high salt induces gastric intraepithelial neoplasia in B6129 mice. *Cancer Res* 2005;65:10709–15.
35. **Lim JW**, Kim H, Kim KH. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. *Lab Invest* 2001;81:349–60.
36. **Smith WL**, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. *J Biol Chem* 1996;271:33157–60.
37. **Karin M**. Nuclear factor-kappaB in cancer development and progression. *Nature* 2006;441:431–6.
38. **Nishinaka Y**, Nishiyama A, Masutani H, *et al.* Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. *Cancer Res* 2004;64:1287–92.
39. **Wang Z**, Rong YP, Malone MH, *et al.* Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. *Oncogene* 2006;25:1903–13.
40. **Wang Y**, De Keulenaer GW, Lee RT. Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. *J Biol Chem* 2002;277:26496–500.
41. **Kim JM**, Kim JS, Jung HC, *et al.* *Helicobacter pylori* infection activates NF-kappaB signaling pathway to induce iNOS and protect human gastric epithelial cells from apoptosis. *Am J Physiol Gastrointest Liver Physiol* 2003;285:G1171–80.
42. **Schmid RM**, Adler G. NF-kappaB/rel/ikappaB: implications in gastrointestinal diseases. *Gastroenterology* 2000;118:1208–28.
43. **Lindholm C**, Quiding-Jarbrink M, Lonroth H, *et al.* Local cytokine response in *Helicobacter pylori*-infected subjects. *Infect Immun* 1998;66:5964–71.
44. **Peek RM Jr**, Miller GG, Tham KT, *et al.* Heightened inflammatory response and cytokine expression in vivo to cagA+ *Helicobacter pylori* strains. *Lab Invest* 1995;73:760–70.
45. **Jain SS**, Bird RP. Elevated expression of tumor necrosis factor-alpha signaling molecules in colonic tumors of Zucker obese (fa/fa) rats. *Int J Cancer* 2010;127:2042–50.
46. **Onizawa M**, Nagaishi T, Kanai T, *et al.* Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. *Am J Physiol Gastrointest Liver Physiol* 2009;296:G850–9.
47. **Toller IM**, Hitzler I, Sayi A, *et al.* Prostaglandin E2 prevents *Helicobacter*-induced gastric preneoplasia and facilitates persistent infection in a mouse model. *Gastroenterology* 2010;138:1455–67.
48. **Tanigawa T**, Watanabe T, Hamaguchi M, *et al.* Anti-inflammatory effect of two isoforms of COX in *H. pylori*-induced gastritis in mice: possible involvement of PGE2. *Am J Physiol Gastrointest Liver Physiol* 2004;286:G148–56.
49. **Li GQ**, Xia HH, Chen MH, *et al.* Effects of cyclooxygenase-1 and -2 gene disruption on *Helicobacter pylori*-induced gastric inflammation. *J Infect Dis* 2006;193:1037–46.
50. **Lee CW**, Rickman B, Rogers AB, *et al.* Combination of sulindac and antimicrobial eradication of *Helicobacter pylori* prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. *Cancer Res* 2009;69:8166–74.

## Gut tutorial

### Copper and liver disease

This is an introduction to the Gut tutorial ‘Copper and liver disease’ hosted on BMJ Learning—the best available learning website for medical professionals from the BMJ Group.

Astute clinical examination may suggest the diagnosis of Wilson’s disease in a patient with typical clinical features. However, often, the confirmation of this diagnosis is difficult. Copper overload can present as a variety of liver and neurological disorders. Not suspecting the diagnosis of Wilson’s disease and delay in confirming the suspected diagnosis remain a problem with this disease. The diagnosis and treatment of Wilson’s disease as well as the newer developments in the understanding of copper metabolism are discussed in this tutorial.

To access the tutorial (Interactive Case History), click on **BMJ Learning: Take this module on BMJ Learning** from the content box at the top right and bottom left of the online article. For more information please go to: <http://gut.bmj.com/site/tutorials/>. If prompted, subscribers must sign into Gut with their journal username and password. All users must also complete a one-time registration on BMJ Learning and subsequently log in (with a BMJ Learning username and password) on every visit.

**C E Eapen**<sup>1,2,3,4</sup>

<sup>1</sup>Department of Hepatology, Christian Medical College, Vellore, Tamil Nadu, India; <sup>2</sup>Department of Clinical Biochemistry, Christian Medical College, Vellore, Tamil Nadu, India; <sup>3</sup>Department of Pathology, Christian Medical College, Vellore, Tamil Nadu, India; <sup>4</sup>Department of Ophthalmology, Christian Medical College, Vellore, Tamil Nadu, India

**Correspondence to** C E Eapen, Department of Hepatology, Christian Medical College, Vellore, Tamil Nadu, India 632004; [eapen@cmcvellore.ac.in](mailto:eapen@cmcvellore.ac.in)

**Patient consent** Obtained.

**Provenance and peer review** Commissioned and externally reviewed.

*Gut* 2012;61:63. doi:10.1136/gutjnl-2011-301743



## Copper and liver disease

C E Eapen

*Gut* 2012 61: 63

doi: 10.1136/gutjnl-2011-301743

---

Updated information and services can be found at:

<http://gut.bmj.com/content/61/1/63>

---

*These include:*

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

**Errata** An erratum has been published regarding this article. Please see [next page](#) or: </content/61/5/773.full.pdf>

### Notes

---

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>

8. **Chu CJ**, Lok AS. Clinical significance of hepatitis B virus genotypes. *Hepatology* 2002;**35**:1274–6.
9. **Kao JH**. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. *J Gastroenterol Hepatol* 2002;**17**:643–50.
10. **Miyakawa Y**, Mizokami M. Classifying hepatitis B virus genotypes. *Intervirology* 2003;**46**:329–38.
11. **Kimbi GC**, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. *J Gen Virol* 2004;**85**:1211–20.
12. **Kramvis A**, Weitzmann L, Owiredu WK, et al. Analysis of the complete genome of subgroup A' hepatitis B virus isolates from South Africa. *J Gen Virol* 2002;**83**:835–9.
13. **Sugauchi F**, Kumada H, Acharya SA, et al. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. *J Gen Virol* 2004;**85**:811–20.
14. **Sugauchi F**, Kumada H, Sakugawa H, et al. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. *Clin Infect Dis* 2004;**38**:1222–8.
15. **Sugauchi F**, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. *Gastroenterology* 2003;**124**:925–32.
16. **Tanaka Y**, Orito E, Yuen MF, et al. Two subtypes (subgenotypes) of hepatitis B virus genotype C: a novel subtyping assay based on restriction fragment length polymorphism. *Hepatal Res* 2005;**33**:216–24.
17. **Akuta N**, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. *J Hepatol* 2003;**38**:315–21.
18. **Tanaka Y**, Hasegawa I, Kato T, et al. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. *Hepatology* 2004;**40**:747–55.
19. **Orito E**, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology* 2001;**34**:590–4.
20. **Kobayashi M**, Arase Y, Ikeda K, et al. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. *J Med Virol* 2002;**68**:522–8.
21. **Ogawa M**, Hasegawa K, Naritomi T, et al. Clinical features and viral sequences of various genotypes of hepatitis B virus compared among patients with acute hepatitis B. *Hepatal Res* 2002;**23**:167–77.
22. **Takeda Y**, Katano Y, Hayashi K, et al. Difference of HBV genotype distribution between acute hepatitis and chronic hepatitis in Japan. *Infection* 2006;**34**:201–7.
23. **Yotsuyanagi H**, Okuse C, Yasuda K, et al. Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. *J Med Virol* 2005;**77**:39–46.
24. **Kato H**, Orito E, Sugauchi F, et al. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. *J Virol Methods* 2003;**110**:29–35.
25. **Orito E**, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* 2001;**33**:218–23.
26. **Kato H**, Orito E, Gish RG, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. *Hepatology* 2002;**35**:922–9.
27. **Sugiyama M**, Tanaka Y, Sakamoto T, et al. Early dynamics of hepatitis B virus in chimeric mice carrying human hepatocytes monoinfected or coinfecting with genotype G. *Hepatology* 2007;**45**:929–37.
28. **Koyama T**, Matsuda I, Sato S, et al. Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981–1992) and epidemiological evidence for its efficacy. *Hepatal Res* 2003;**26**:287–92.
29. **Noto H**, Terao T, Ryou S, et al. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980–1994. *J Gastroenterol Hepatol* 2003;**18**:943–9.
30. **Tanaka J**, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. *Intervirology* 2004;**47**:32–40.
31. **Daniels D**, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. *MMWR Surveill Summ* 2009;**58**:1–27.
32. **Goldstein ST**, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. *J Infect Dis* 2002;**185**:713–19.
33. **Sherlock S**. The natural history of hepatitis B. *Postgrad Med J* 1987;**63** Suppl 2:7–11.
34. **Mayerat C**, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? *J Viral Hepat* 1999;**6**:299–304.
35. **Hayashi K**, Katano Y, Takeda Y, et al. Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. *J Gastroenterol* 2008;**43**:558–64.
36. **Ozasa A**, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. *Hepatology* 2006;**44**:326–34.
37. **Matsuura K**, Tanaka Y, Hige S, et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. *J Clin Microbiol* 2009;**47**:1476–83.
38. **Bodsworth NJ**, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. *J Infect Dis* 1991;**163**:1138–40.
39. **Li JS**, Tong SP, Wen YM, et al. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. *J Virol* 1993;**67**:5402–10.
40. **Suzuki Y**, Kobayashi M, Ikeda K, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *J Med Virol* 2005;**76**:33–9.
41. **Sugauchi F**, Orito E, Ohno T, et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. *Hepatal Res* 2006;**36**:107–14.
42. **Norder H**, Courouge AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004;**47**:289–309.

## Correction

**Eapen CE**, et al. Gut tutorial, *Copper and liver disease*. *Gut* 2012;**61**:63. doi:10.1136/gutjnl-2011-301743. The following author names should have been included in the author list:

Suresh Kumar,<sup>1</sup> J J Fleming,<sup>2</sup> B Ramakrishna,<sup>3</sup> L Abraham,<sup>4</sup> J Ramachandran,<sup>1</sup>

<sup>1</sup>Department of Hepatology, Christian Medical College, Vellore, Tamil Nadu, India

<sup>2</sup>Department of Clinical Biochemistry, Christian Medical College, Vellore, Tamil Nadu, India

<sup>3</sup>Department of Pathology, Christian Medical College, Vellore, Tamil Nadu, India

<sup>4</sup>Department of Ophthalmology, Christian Medical College, Vellore, Tamil Nadu, India

*Gut* 2012;**61**:773. doi:10.1136/gutjnl-2011-301743corr1